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A B S T R A C T
Recent years have witnessed a substantial increase in the number of seric determinations 
of vitamin D, in a worldwide basis. At Hospital das Clínicas of Faculdade de Medicina of 
Universidade de São Paulo that increase reached 700% over the last four years. Nevertheless 
there are many controversies on the literature about the role of vitamin D in conditions 
unrelated to the musculoskeletal system. In this study the metabolism, sources and actions 
of vitamin D on the body are reviewed. Observational studies, clinical trials, systematic 
reviews and metanalysis which focused on the relationship between the vitamin and 
conditions such as cancer, cardiovascular disease, diabetes and falls were searched on the 
literature, analyzed and discussed. Results are presented as quiz and answer, tables and 
a figure. The role of vitamin D on the above-mentioned conditions is discussed, and the 
controversial issues stressed.
© 2013 Elsevier Editora Ltda. 
Vitamina D: ações extraósseas e uso racional
R E S U M O
O número de dosagens do nível sérico de vitamina D tem apresentado crescimento muito 
expressivo nos últimos anos em todo o mundo. No Hospital das Clínicas da Faculdade de 
Medicina da Universidade de São Paulo houve aumento de cerca de 700% em quatro anos nas 
solicitações desse hormônio. No entanto, há controvérsias na literatura sobre a real utilidade 
de sua dosagem e/ou suplementação, exceto em situações diretamente relacionadas 
ao metabolismo ósseo. No presente trabalho são revistos o metabolismo, as fontes e as 
ações da vitamina D no organismo. Estudos observacionais, ensaios clínicos, revisões 
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sistemáticas e metanálises, cujo foco é a relação entre vitamina D e doenças ou condições 
clínicas, como câncer, doenças cardiovasculares, diabetes e quedas, foram pesquisados na 
literatura, analisados e discutidos. Os resultados estão apresentados em forma de perguntas 
e respostas, tabelas e figura. Discute-se o papel da vitamina D em todas essas situações, e 
salientam-se os pontos controvertidos.
Introduction
Context
The number of ordered laboratory tests has been rising steadily 
worldwide, among them, vitamin D measurement. The number 
of such analyses in the Hospital das Clínicas of the Faculdade de 
Medicina da Universidade de São Paulo (HC-FMUSP) increased 
from 6,810 in 2007 to 52,997 in 2011, with a further increase of 
60% in 2012, which occurred without an equivalent increase 
number of patients attended to in the same period. This is 
probably caused by the recent exponential increase in the 
number of published studies in medical literature addressing 
the possible role of vitamin D in different clinical situations, 
not only those related to bone metabolism.1 Studies conducted 
in the United States demonstrated that three quarters of the 
White population and 90% of individuals of Black, Hispanic, 
and Asian descent in the US have low blood levels of vitamin D.
It is estimated that over 1 billion people worldwide have 
low vitamin D levels,2 which appears to constitute an actual 
“epidemic” of hypovitaminosis D, with possible serious 
consequences for public health. Alternatively, it can be argued 
that low serum levels of vitamin D may merely be an indicator 
of unhealthy life habits or poor health, and, except in cases of 
rickets and osteomalacia, they may not necessarily be involved 
in the cause of other diseases. 
The present study reviewed the physiology of vitamin D 
and its measurement methods, and critically evaluated the 
latest evidence on some of the possible extra-osseous effects 
of vitamin D as shown by clinical trials, systematic reviews, 
meta-analyses, and traditional reviews in the literature, as well 
as the recommendations of different international societies for 
its measurement and supplementation.
Sources of vitamin D
The main forms of biological vitamin D or calciferol (the group 
of chemical substances related to vitamin D) in nature and the 
human body are shown in Table 1.
The need for vitamin D is 600 IU/day for individuals aged 
1 to 70 years, and 800 IU/daily for those older than 70 years, 
which results in serum levels > 20 ng/mL, provided there is a 
minimum level of sun exposure. 
Serum levels of vitamin D are influenced by several factors, 
such as obesity, sun exposure, physical activity, nutritional 
status, skin pigmentation, and medications. Patients who 
have undergone bariatric surgery and patients with chronic 
renal failure have a higher risk of vitamin D deficiency. Black 
individuals require a three to five times longer sun exposure 
than whites to produce the same amount of vitamin D. The 
use of sun protection factor 30 sunscreen reduces vitamin D 
production by over 95%. Anticonvulsants and antiretroviral 
drugs accelerate the catabolism of vitamin D. Endogenous 
sources of vitamin D last twice as long in the body than 
exogenous ones.2,3
The following presents the amount of vitamin D in each 
food:
Codfish liver oil 400-1.000 IU/one teaspoon (D3)
Fresh wild salmon 600–1.000 IU/100 mL (D3)
Fresh farmed salmon 100-250 IU/100 mL (D3, D2)
Canned salmon 300-600 IU/100 mL (D3)
Canned sardines 300 IU/100 mL (D3)
Canned mackerel 250 IU/100 mL (D3)
Canned tuna 236 IU/100 mL (D3) 
Fresh shiitake mushrooms 100 IU/100 mL (D2)
Dried shiitake mushrooms 1.600 IU/100 mL (D2)
Egg yolk 20 IU/unit (D3, D2)
Metabolism
The major source of vitamin D is the epidermis. Vitamin D3 is 
produced in the skin by a reaction mediated by ultraviolet B 
(UVB) radiation, whose wavelength is in the range of 290 
to 315 nm. This is a photolytic reaction, not enzymatic, 
and converts 7-dehydrocholesterol into pre-vitamin D3. 
Pre-vitamin D3 undergoes another non-enzymatic reaction, 
which produces a thermal isomerization in the skin, reaching 
a vitamin D peak in 30 to 60 days after sun exposure. From 
Nomenclature Characteristic
Cholecalciferol 
 or vitamin D3
Present in foods of animal origin 
and vitamin supplements
Ergocalciferol 
 or vitamin D2
Present in liver oil of cod and 
other fish (salmon, mackerel and 
herring), as well as vegetables 
sources and mushrooms
Calcifediol or calcidiol 
 or 25-hydroxyvitamin-D3 
 or 25(OH)D3
Form usually measured in the 
human body, has a half-life of 
two to three weeks
Calcitriol 
 or 1,25-dihydroxyvitamin-D3 
 or 1,25(2OH)D3
Active form in the human body, 
has a half-life of four hours, 
and can be measured in specific 
clinical conditions
Table 1 – Vitamin D in nature and the human body.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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the skin, vitamin D3 enters the circulation and reaches 
the liver, where the P450-family enzymes convert it into 
25-hydroxyvitamin-D3 or 25(OH)D3 (calcidiol). 25(OH)D3 binds 
to serum proteins, remaining as the most stable metabolite 
of vitamin D; its measurement is the most suitable test for 
assessing body status. It is related to the dermal synthesis and 
ingestion.4
25(OH)D3  is converted into 1,25-dihydroxyvitamin D 
or 1,25(2OH)D3 (calcitriol) by the mitochondrial enzyme 
CYP27B1-hydroxylase of the epithelial cells in the proximal 
renal tubules (Fig. 1). 1,25(2OH)D3 binds to high-affinity tissue 
receptors, modulating gene expression and subsequent actions. 
Its concentration is approximately 0.1% of that of 25(OH)
D3 prohormone. Its synthesis is stimulated by the parathyroid 
hormone (PTH) and inhibited by the fibroblast growth factor 23 
(FGF23), produced in osteocytes. Thus, a decrease in 25(OH)D3 
stimulates PTH production. 
In the intestine, vitamin D stimulates calcium and 
phosphorus absorption. Without vitamin D, only 10% to 
15% of the calcium and 60% of the phosphorus in the diet 
Fig. 1 – Vitamin D metabolism and nomenclature.
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is absorbed.2 At sufficient levels, vitamin D increases the 
absorption of calcium to 30% to 40% and the absorption of 
phosphorus to 80%. 1,25(2OH)D3 binds to specific receptors 
(vitamin D receptors [VDR]) of osteoblasts, stimulating 
RANK-ligand expression. The latter interacts with the receptor 
activator of nuclear factor kappa-b, which induces the 
immature monocytes to develop into mature osteoclasts, which 
in turn release the stores of calcium from bones. Furthermore, 
from the evolutionary point of view, vitamin D produces 
a cytokine that protects the cell from microbial invasion. This 
cytokine is produced by monocytes/macrophages, and has an 
intracellular action.5
Methods of laboratory measurement and reference values
The measurement of serum 25(OH)D3 is useful in the eva-
luation of the body load of vitamin D, as well as in the diffe-
rential diagnosis of hypercalcemia (which includes exogenous 
poisoning). The measurement of serum 1,25(2OH)D3 is 
indicated in chronic renal failure, hypercalcemia associated 
with granulomatous diseases, and vitamin D-dependent 
rickets type I. 
Currently, the ideal methods for measuring 25(OH)D3 are 
based on high-performance liquid chromatography (HPLC) 
or liquid chromatography with tandem mass spectrometry 
detection (LC-MS/MS). In practice, however, automated 
immunoassays are the methods most commonly used by 
clinical laboratories. This method simultaneously measures 
25(OH)D2 and 25(OH)D3. HPLC and mass spectrometry are 
capable of differentiating between these two forms, providing 
distinct results for each of the fractions.6
The optimal serum level of 25(OH)D3  is yet to have a 
consensus in the literature. In theory, the optimal level of 
vitamin D would be that required to maintain adequate levels 
of PTH. The decrease in calcium absorption by the intestine 
causes a decrease in plasma calcium levels, which activates 
calcium-sensing receptors in the parathyroid membrane, 
releasing PTH and increasing PTH gene expression.7
The interaction of PTH with PTH receptor/PTHrP of the 
epithelial cell membrane of the renal tubules leads to an 
increase in CYP2/B1  gene. This converts 25(OH)D3  into 
1,25(2OH)D3. This vitamin binds to serum proteins, reaching 
the cells containing vitamin D receptors. In the intestine, they 
promote calcium and phosphorus absorption, and in the bone, 
they release calcium and phosphorus from the mineral matrix. 
When there is normalization of serum calcium levels, FGF23 is 
released by the bones, interrupting the process.8
This knowledge led to the improvement of the definition of 
vitamin D insufficiency and deficiency in terms of the increase 
of immunoreactive serum PTH (iPTH). iPTH increases when 
the serum levels of 25(OH)D3 decrease to less than 30 ng/mL 
or 75 nmol/L.
The American Society of Endocrinology suggests the 
following reference values for 25(OH)D3:
• Deficiency: ≤ 20 ng/mL
• Insufficiency: 21 to 29 ng/mL
• Optimal: ≥ 30 ng/mL
Skeletal abnormalities are observed only in cases of 
vitamin D deficiency. In the U.S., 25% to 35% of the female 
population is included in this group. There are some plausible 
explanations for this fact: decrease in milk consumption 
(fortified with vitamin D), use of sunscreens, decreased 
sun exposure, and increased body mass index of the U.S. 
population.8
Methods
Systematic and traditional literature reviews, meta-
analyses, and major clinical trials regarding vitamin D 
measurement and/or supplementation and the possible 
association with cancer, cardiovascular disease (CVD), 
diabetes, and falls were searched in the MEDLINE, PubMed, 
and SciELO databases.
This literature search identified articles submitted to 
critical evaluation, taking the following questions as common 
methodological denominators for each type of clinical 
situation: 
• Is there is any biological plausibility regarding the hypo-
thesis that vitamin D is associated with the clinical situa-
tion?
• Is there any epidemiological evidence associating serum 
vitamin D levels with the clinical situation in humans?
• Are there systematic reviews of these studies on the 
asso ciation of vitamin D with the clinical situation in 
humans?
• Is this evidence conclusive in itself?
• Are there any randomized controlled trials (RCTs) evalua-
ting the association of vitamin D supplementation with 
morbidity and mortality?
• Can it be concluded that vitamin D is associated with morbi-
dity and mortality and that its replacement can prevent 
them?
After analyzing all the specific literature, the consolidated 
findings were grouped by clinical situations, and then the 
findings were homogenized to allow for the presentation of 
results and drawing of conclusions. 
Results
The answers to the analyzed clinical situations are detailed 
below, and summarized in Table 2. 
Cancer
Is there is any biological plausibility regarding the hypothesis that 
vitamin D is associated with cancer? 
Yes. Studies in cell cultures and experimental animal 
models suggest that 1,25(2OH)D3 (calcitriol) promotes cell 
differentiation, inhibits vascular and cancer cell proliferation, 
and also presents anti-inflammatory and proapoptotic 
properties.9
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Groups 
of diseases
 
Results of meta-analysis of cohort and case-control 
studies (association between serum 25(OH)D3 
and incidence/mortality) 
Results of randomized and controlled trials 
(cause-effect association between vitamin D 
supplementation and incidence/mortality) 
Cancer –  Increased mortality in men with higher levels 
of 25(OH)D3 (with levels varying between studies) 
(Chung, 2011)
–  No association between serum levels of vitamin D 
with prostate, breast, endometrial, esophageal, 
stomach, kidney, non-Hodgkin lymphoma, and 
ovarian cancers (Helzlsouer, 2010)
–  Increased risk of pancreatic cancer with plasma levels 
of 25(OH)D3 > 40 ng/mL (Helzlsouer, 2010)
–  6% lower incidence of colorectal cancer for each 
increment of 5 ng/mL of serum levels of 25(OH)D3 
(Chung, 2011)
–  No cause-effect association was observed between the 
supplementation of 400 IU vitamin D/day + calcium 
(control group = placebo) with the incidence or mortality 
from overall cancer, colorectal cancer, and breast cancer 
(Manson, 2011)
–  No cause-effect association was observed between the 
supplementation of 100,000 IU of vitamin D/every four 
months (± 833 IU/day) + calcium (control group = placebo) 
with the incidence or mortality from overall cancer, 
colorectal cancer, and breast cancer (Manson, 2011)
–  Reduced incidence (0.40, 95% CI = 0.20 to 0.82) and 
mortality (0.23, 95% CI = 0.09 to 0.60) of overall cancer, 
with supplementation of 1,100 IU of vitamin D/day +
+ calcium (control group = only calcium) (Chung, 2011)
Cardiovascular 
 disease 
–  Increased incidence of SAH (1.76, 95% CI = 1.27 to 2.44) 
with lower levels of 25(OH)D3 (Pittas, 2010)
–  Relative risk of CVD incidence and mortality and 
mortality from stroke, ranging from 0.8, with 
serum vitamin D levels of 30 ng/mL to 2.2 
with vitamin D levels < 10 ng/mL (Pittas, 2010)
–  There was no consistent association between 
genotypic scores or individual SNPs related to 
vitamin D concentrations with acute myocardial 
infarction and mortality or risk factors for CVD 
(Jorde, 2012)
–  Marginal reduction in mortality from all causes in patients 
receiving vitamin D + calcium (0.91, 95% CI = 0,84-0.98); 
NTT = 151 in three years, and no significant effect for 
those who received only vitamin D (Rejnmark, 2012)
–  No difference was found in CRP levels and arterial flows 
in women with a mean age of 63 years who received 
vitamin D or placebo (Gepner, 2012)
–  There was no significant variation in systolic (–1.9, 95% 
CI = –4.2 to 0.4) and diastolic BP (–0.1, 95% CI = –0.7 to 
0.5) between individuals receiving vitamin D or placebo, 
despite the significant change in serum levels of 25(OH)
D3 in the study group (which received vitamin D) (Pittas, 
2010)
–  No difference was found between vitamin D 
supplementation and placebo regarding acute 
myocardial infarction, stroke, and TIA (Pittas, 2010)
Diabetes 
 mellitus
–  There are no studies showing changes in mortality
–  The National Health and Nutrition Survey (NHANES III) 
showed an inverse association between serum levels 
of 25(OH)D3 and incidence of diabetes mellitus type 2 
(Looker, 2002)
–  The Women’s Health Initiative showed no protective 
effect of 400 UI/day of vitamin D on the incidence
of diabetes mellitus type 2 (De Boer, 2008)
–  The daily supplementation with 4,000 IU 
of vitamin D reduced insulin resistance when levels 
of 25(OH)D3 ≥ 32 ng/mL (Hurst, 2010)
–  There is no difference in the prevalence of diabetes 
mellitus type 2 among individuals with low or high 
levels of 25(OH)D3, except in the subgroup of Black 
individuals, in whom the prevalence of diabetes is 
higher in individuals with lower plasma levels 
of vitamin D (Parker, 2010)
–  A systematic review and meta-analysis of six studies 
led the authors to conclude that there is no effect of 
vitamin D on the incidence of diabetes mellitus type 2 
in previously healthy individuals, but there may be some 
benefit to those with glucose intolerance (Pittas, 2007)
–  Another systematic review and meta-analysis of 
eight other studies similarly concluded there was 
no statistically significant effect of vitamin D in 
individuals with normal basal glucose or stable 
diabetes; however, in the subgroup whose basal glucose 
was altered, vitamin D supplementation (700 IU/day) 
improved later glycemic control(Pittas, 2010)
Falls –  Meta-analysis of five RCTs showed lower risk of falls 
(OR 0.78, 95% CI = 0.64 to 0.92) in patients receiving 
vitamin D, compared to calcium alone or placebo 
(Bischoff-Ferrari, 2004)
–  In a controlled study of 3,717 institutionalized elderly 
individuals, vitamin D supplementation did not reduce 
the incidence of falls or fractures (Law, 2006)
–  Meta-analysis of RCTs showed the reduction of falls 
in individuals supplemented with 700 IU/day or more 
of vitamin D (Bischoff-Ferrari, 2009)
–  Supplementation of 500,000 IU/year of vitamin D did not 
reduce the number of falls in 2,256 non-institutionalized 
Australian women (Sanders, 2010)
95% CI, 95% confidence interval; CRP, C-reactive protein; SAH, systemic arterial hypertension; CVD, cardiovascular disease; RCT, randomized 
controlled trial. 
Table 2 – Results of the main studies that assessed the association between serum levels of 25 (OH) D3 or vitamin D 
supplementation and the incidence or mortality of different groups of diseases and clinical situations.
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Is there any epidemiological evidence associating serum vitamin D 
levels with cancer in humans? 
Yes. Ecological correlations (e.g., increased incidence of cancer 
in countries with less sun exposure, higher cancer mortality 
in the winter and among black individuals) and some isolated 
observational studies (cohort and case-control) associated 
low serum 25(OH)D3 levels with higher cancer incidence and 
mortality, although other studies have not confirmed this 
association.10
Are there systematic reviews of these studies on the association of 
vitamin D with cancer in humans?
Yes. Meta-analyses of observational studies have suggested a 
possible association between higher levels of vitamin D and a 
slight reduction in the incidence of colorectal cancer, increased 
mortality from overall cancer (only in men), and no association 
with prostate and breast cancer.10 The pooled analysis of ten 
cohort studies included in the “Vitamin D pooling project” 
also found no significant association of vitamin D with less 
common cancers (endometrial, esophageal, stomach, kidney, 
non-Hodgkin lymphoma, ovarian, and pancreatic). On the 
contrary, a higher risk of pancreatic cancer was associated with 
serum concentrations of vitamin D > 40 ng/mL.11
Is this evidence conclusive in itself?
No. The ambiguity of the results obtained from observational 
studies may be due to confounding factors, such as obesity 
(adipose tissue sequesters vitamin D), sedentary lifestyle (little 
sun exposure), black skin (decreased production of vitamin D, 
even with sun exposure), and type of diet (low vitamin intake). 
Furthermore, these studies are subject to reverse bias, that is, 
the person with cancer tends to be more reclusive, to decrease 
sun exposure, to be undernourished, and thus to have lower 
serum levels of vitamin D. 
Are there any RCTs evaluating the association of vitamin D 
supplementation with cancer incidence and mortality?
Yes. Although, to date, no RCTs evaluating the supplementation 
of vitamin D and cancer incidence and mortality as primary 
outcomes have been finalized, some RCTs have allowed for 
the analysis of both as secondary outcomes. In the largest of 
them, the Women’s Health Initiative (WHI), which followed 
36,282 women between 50 and 79 years for seven years, divided 
into two groups (placebo vs. 400 IU vitamin D/day + calcium), 
there was no difference either in cancer incidence or mortality.
[12] Similar results were observed in two other RCTs developed 
in Oxford, UK, and in Nebraska, USA; however, in the latter, 
the comparison of two study subgroups (calcium vs. 1,000 IU 
vitamin D/day + calcium) showed a significant reduction in 
overall cancer incidence and mortality.9,10
Can it be concluded that low vitamin D levels are associated with 
higher cancer incidence and mortality and that its replacement can 
prevent it? 
No. In light of the best available scientific evidence, it is 
premature to consider that lower serum levels of vitamin D 
may, by themselves, increase cancer incidence or morta-
lity, and justify supplementation for disease prevention.12 
To support good medical recommendations, other RCTs are 
still needed, with more diverse target populations, higher dose 
vitamin D supplementation (≥ 800 IU/day), longer duration of 
follow-up in the study groups, and with cancer incidence and 
mortality as primary outcomes. 
Cardiovascular diseases 
Is there is any biological plausibility regarding the hypothesis that 
vitamin D is associated with CVD? 
Yes. Experimental laboratory studies have suggested possible 
mechanisms of action or influence of vitamin D on the 
cardiovascular system. For example, vitamin D deficiency 
activates the renin-angiotensin-aldosterone system, which can 
lead to systemic arterial hypertension (SAH) and left ventricular 
(LV) hypertrophy. Another consequence of deficiency is the 
increase in PTH, which leads to increased insulin resistance, 
diabetes mellitus type 2, SAH, and inflammation. Vitamin D 
inhibits the proliferation of cardiomyoblasts by promoting 
cell cycle arrest, and increases cardiomyotubule formation, 
without inducing apoptosis. It has also been observed that 
vitamin D attenuates LV dysfunction in animal models and 
humans. 
Is there any epidemiological evidence associating serum vitamin D 
levels with CVD in humans? 
Yes. Cross-sectional studies have raised the suspicion 
of this association (e.g., the incidence of cardiovascular 
disease is higher in population groups with lower levels of 
vitamin D, and vice-versa). A Korean survey conducted in 
2008-2009 demonstrated an association between lower levels 
of vitamin D and higher CVD mortality.13 Isolated observational 
studies have shown an association between lower serum levels 
of 25(OH)D3 and increased CVD incidence and/or mortality, 
including SAH and coronary heart disease, although there are 
other studies that did not show this association. 
Are there systematic reviews of these studies on the association of 
vitamin D with CVD in humans? 
Yes. Regarding SAH, a meta-analysis of three cohort studies, 
which totaled 32,181 individuals followed-up between seven 
and ten years, showed increased risk among individuals with 
low blood levels of vitamin D. A systematic review of seven 
cohorts (n = 43,527; five to 27 years of follow-up) demonstrated 
a trend of inverse correlation between vitamin D levels and 
CVD incidence and mortality, including coronary heart and 
cerebrovascular disease.[14] In addition to these, part of the 
Tromso study was recently published, which longitudinally 
evaluated the association between the presence of genetic 
polymorphisms related to vitamin D and a) outcomes 
(myocardial infarction and mortality), b) risk factors for CVD; 
no consistent association was identified.15
Is this evidence conclusive in itself?
No. The evidence is insufficient for the same reasons described 
for cancer, especially regarding the methodological limitations 
inherent to observational studies, which cannot be used to 
demonstrate the cause-effect association between variables, 
only possible associations.
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Are there any RCTs evaluating the association of vitamin D 
supplementation with CVD incidence and mortality? 
Yes. A meta-analysis of clinical trials that included 
70,528  individuals with a median age of 70 years (86.8% 
women), whose intervention groups received varying doses of 
vitamin D, alone or in combination with calcium, demonstrated 
a borderline reduction in mortality in individuals receiving 
vitamin D + calcium (RR = 0.91, 95% CI = 0.84 to 0.98) and no 
statistically significant effect on those receiving vitamin D 
only.16 Another RCT, in which C-reactive protein (CRP) levels 
and arterial blood flows were measured in 114 women who 
received 25,000  IU/day of vitamin D3 or placebo showed 
no difference between the groups after four months of 
follow-up.17 In addition to these studies, a meta-analysis 
of ten clinical trials showed no effect of vitamin D on systolic 
or diastolic blood pressure levels, and four other RCTs showed 
no superior effect of vitamin D over placebo on the incidence 
of myocardial infarction, angina pectoris, stroke, and transient 
ischemic attack.14
Can it be concluded that vitamin D is associated with higher 
CVD  incidence and mortality and that its replacement can 
prevent it? 
No. The available RCTs demonstrated no consistent causal 
association between vitamin D supplementation and reduced 
overall CVD incidence or mortality, or from hypertension or 
ischemic heart disease alone. Other ongoing RCTs may provide 
more information. 
Diabetes mellitus
Is there is any biological plausibility regarding the hypothesis that 
vitamin D is associated with diabetes? 
Yes. Several studies indicate the possibility of using vitamin D 
in diabetes mellitus prevention and treatment. Its actions on 
the immune system, for instance, could be useful in patients 
with diabetes mellitus type 1; vitamin D can improve the 
activity of beta cells, either directly through their receptors, or 
indirectly by regulating calcium homeostasis. It can also affect 
insulin sensitivity.18 There is one study that demonstrated the 
worsening of diabetes control, in countries with temperate 
climate, during winter.19
Is there any epidemiological evidence, including systematic reviews, 
associating serum vitamin D levels with diabetes in humans? 
Yes. A cross-sectional study of the National Health and Nutri-
tion Survey (NHANES) in the United States, which included 
9,773 participants, observed that the levels of 25(OH)D3 were 
inversely associated with the prevalence of diabetes mellitus 
type 2, which persisted even after controlling for other 
variables.20
Conversely, although in the systematic review/meta-
analysis by Parker et al.21 the combined results demonstrated 
a decrease in the prevalence of diabetes mellitus type 2 
associated with higher levels of vitamin D, when compared 
with lower levels (OR 0.54, 95% CI = 0.23 to 1.27), the result 
was only significant when the data on Black ethnicity were 
removed (OR = –0.36, 95% CI = 0.16 to 0.80). One of the studies 
included in this review showed a direct association between 
high levels of vitamin D and an increased prevalence of 
diabetes in Black individuals. Another meta-analysis in 2007 
found an inverse association of the incidence of diabetes 
mellitus type 2 when comparing groups with higher and lower 
combined intake of vitamin D and calcium18 (OR = 0.82, 95% 
CI = 0.72 to 0.93).
Is this evidence conclusive in itself?
No. The occurrence of confounders, always possible in 
observational studies, makes it necessary to conduct experi-
mental studies such as RCTs in order to establish a causal 
relationship between vitamin D and several diseases, including 
diabetes. Moreover, there are alternative explanations for the 
findings in these studies. 
Are there any RCTs evaluating the association of vitamin D 
supplementation with diabetes? 
Yes. In the meta-analysis and systematic review by 
Pittas,18 previously mentioned, interventional studies were 
analyzed. There were four small, short-duration studies and 
two of long-duration, all of which were controlled. Only one 
study, including 20 patients with diabetes mellitus type 2, had a 
favorable outcome with vitamin D use, showing improvement 
in insulin and C-peptide secretion in newly diagnosed patients, 
suggesting that vitamin D may slow the progression to clinical 
disease. Considered together, the studies had a limited number 
of participants, were predominantly short-duration, used 
different doses of vitamin D and calcium, and included post 
hoc analysis. The authors concluded for the absence of effects 
in healthy participants and suggested potential usefulness 
of vitamin D and calcium when there is no prior glucose 
intolerance. 
Another meta-analysis included eight studies that evaluated 
the effect of vitamin D on blood glucose. The duration ranged 
from seven months to two years, and doses of vitamin D varied 
from 400 to 5,714 IU/day. Only two trials were considered of 
good quality. In five experiments in which glucose was normal 
at baseline, there was no effect on blood glucose or incidence 
of diabetes. An analysis of subgroups with inadequate blood 
glucose at baseline, and whose patients received 700 IU/day 
of D3 and 500 mg/day of calcium, showed a decrease in the 
tendency to worsened glycemic control, which usually occurs 
in these groups. In two experiments in which participants had 
stable disease, there were no changes after eight and 24 weeks 
of supplementation.14
The Women’s Health Initiative (WHI) study22 is noteworthy 
as it was the largest on vitamin D supplementation, but the 
participants also received calcium: there was no statistically 
significant effect for any of the cardiometabolic effects 
assessed. It included 33,591  women with no history of 
diabetes; intervention consisted of supplementation with 
1,000 mg of calcium and 400 IU of 25(OH)D3/day; the outcome 
was new cases of diabetes. The results after a median 
follow-up of seven years demonstrated a relative risk of 1.01 
(95% CI = 0.94 to 1.10), that is, no risk reduction. The result 
persisted in subgroup analyses, when noncompliance was 
considered and when analyzing only changes in laboratory 
measures.
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Can it be concluded that low vitamin D levels are associated with 
higher diabetes incidence and mortality or that its replacement can 
prevent them?
There are no studies on mortality. According to this latest 
revision by Pittas,14  clinical trials did not confirm the 
cross-sectional studies that showed a consistent association 
between low vitamin D levels and cardiometabolic disorders.
The WHI22 study (that included calcium administration), 
the RCT with the highest number of participants and time 
of follow-up that concluded there was no association, may, 
however, be criticized regarding the following aspects: use of 
low-dose vitamin D (400 IU), difficulty of adherence throughout 
seven years, and allowing the use of supplements in both 
groups (reducing differences). Furthermore, the dose of vitamin 
D employed was too low to lead to a significant increase in 
serum levels.
Due to these criticisms, the study by Hurst,23 published in 
2009, deserves a separate comment: 42 South-Asian women, 
aged between 23 and 67 years, were treated with 4,000 IU of 
25(OH)D3/day and 39 received placebo. At the beginning they 
had insulin resistance (measured by HOMA1) and vitamin 
D < 20 ng/mL. With supplementation, vitamin D increased 
from 8.4 (4.4 -16.0) to 32 ng/mL (26.8-37.6) after six months.
The result showed decreased insulin resistance when 25(OH)
D3 reached levels of 32 ng/mL or more. This was the first RCT 
that used enough supplementation to increase vitamin D to 
these levels, requiring doses of 2,000 IU/day or more when 
basal level was < 5 ng/mL. Although no clinical outcomes 
were studied, the authors argued that in previous studies, 
supplementation was not effective, either because the doses 
were lower, or duration was shorter (the authors did not observe 
significant results before six months). Based on bone markers 
and PTH levels, the authors suggested daily administration, but 
spaced doses can have better effect on adherence. They also 
stated that replacement would be preferable to sun exposure, 
due to the risk of overexposure and interpersonal variation 
of the needs. They finally warn about the critical role of dose 
sufficiency, and the need to verify the safety and effectiveness 
of supplementation with high doses over the long term. 
Falls
Is there is any biological plausibility regarding the hypothesis 
that vitamin D is associated with falls? 
Yes. Several studies have correlated vitamin D supplementation 
with reduced fractures. This decrease could be at least partly 
due to the fact that people fall less often.24
The possible association between falls and vitamin D 
deficiency is based on some findings: a) there are receptors 
for 1,25(2OH)D3 in muscles25,26; b) vitamin D is associated 
with muscle protein synthesis27,28; and c) some studies 
demonstrated that vitamin D improves muscle function and 
may reduce falls, especially when associated with calcium.29,30
There are also studies that show that PTH induces muscle 
catabolism, that is, when there is vitamin D deficiency, the 
increase in this hormone would damage muscle. Another 
hypothesis is decreased reflexes in individuals with vitamin 
D deficiency, explaining falls regardless of muscle injury. 
Is there any evidence associating serum vitamin D levels with falls 
in humans? 
Yes, but the results are conflicting. Vitamin D deficiency in 
individuals aged > 65 years occurs in 40% to 50% of individuals 
who have no history of falls, and in 70% of those with a 
tendency to repeated falls.31-33 Conversely, there appears 
to be a physiological decrease in muscle strength with age, 
which is not prevented by supplementation with vitamin 
D34,35; it has been shown that multiple comorbidities also 
cause muscle weakness, which is improved by vitamin D 
supplementation.36
In a review of the causal mechanisms involved in falls, the 
authors observed an association of vitamin D deficiency with 
muscle disorders. However, when adjusted for other variables, 
such as age, physical activity, body mass index, and chronic 
diseases, this association disappeared.37 Neuromuscular 
improvement after supplementation, when it occurs, appears 
to depend mainly on levels prior to replacement. 
Other studies demonstrated that: a) supplementation 
with vitamin D and calcium in 148  elderly women who 
were vitamin  D deficient (<  20  ng/mL) resulted in a 9% 
improvement in stability and fewer falls during a one-year 
follow up, compared to calcium supplementation alone38; 
b) supplementation of 400  IU/day of vitamin D did not 
reduce falls in 354 Dutch institutionalized elderly individual 
aged > 70 years39; c) vitamin D supplementation (compared 
to placebo) did not influence falls in 389 elderly outpatients, 
although this study did not measure levels of vitamin D40; 
d) in a controlled study with 3,717 institutionalized elderly 
individuals, vitamin D supplementation did not reduce falls 
or fractures.41
The results of some of these studies have hypothesized 
that the lack of effect of vitamin D on falls in the elderly is 
due to the fact that they are institutionalized and therefore 
under better environmental control. However, Venning et al. 
stated that lack of improvement regarding falls with vitamin 
D supplementation, observed by some researchers, would 
not be due to this fact but to instead due to the low doses of 
vitamin D used in the supplementation.42 Indeed, studies with 
institutionalized elderly have shown improvement with doses 
of 800 IU/day, which does not occur when the replacement 
dose is 400 IU/day as discussed below. There is, however, no 
direct comparison between doses. 
In a double-blinded, randomized study with 139 outpatients 
aged > 65 years who had a history of falls and vitamin D 
levels ≤ 12 ng/mL, the study group received a single dose 
of 600,000 IU of intramuscular ergocalciferol. The time of 
functional neuromuscular performance, time of psychomotor 
reaction, and balance improved significantly. However, muscle 
strength did not change, and there was no difference in the 
frequency of falls. This only suggests a vitamin D action on 
neuromuscular function in patients with vitamin D deficiency, 
with no effect on falls.43
Finally, in a recent controlled study of annual supplemen-
tation with high doses of vitamin D (500,000 IU/year), Sanders 
et al. observed no reduction in falls among 2,256 non-ins-
titutionalized Australian elderly women. In fact, the falls even 
increased. In this study, basal levels of vitamin D were not 
different between the two groups44 (21 vs. 18 ng /mL).
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Is this evidence conclusive in itself?
No. Methodological variations may be responsible for 
conflicting results, as the magnitude of the supplementation 
benefit depends on gender (women more than men); on 
whether the individual is institutionalized or not (non-ins-
titutionalized more than institutionalized); levels prior to 
supplementation (higher gain if basal levels are lower); dose 
(the benefit is greater with doses > 800 IU/day); and presence 
of multiple comorbidities (when there are no comorbidities, 
the benefit is greater). 
If there is an association of vitamin D with falls, this 
occurs mainly in non-institutionalized elderly individuals 
with vitamin deficiency. This might be due to the fact 
that institutionalized women have multiple comorbidities 
that result in falls. The association of vitamin D deficiency 
with falls appears to be more due to the action of vitamin D 
on neuromuscular function than on muscle strength itself.
Are there systematic reviews of RCTs that evaluated vitamin D 
supplementation on the incidence and mortality of falls?
Yes. In a first meta-analysis, Bischoff-Ferrari et al. analyzed 
five randomized and controlled trials involving 1,237 elderly 
patients with stable health status, and concluded that 
supplementation with vitamin D reduces falls by 22% 
(OR = 0.78, 95% CI = 0.64 to 0.92) when compared to calcium 
supplementation or placebo, with a number needed to treat 
(NNT) of 15 during the study period. The effect was significant 
only in women. However, serum levels of vitamin D were not 
measured and the level of physical activity was not quantified; 
moreover, the vitamin D dose was not established, as well as 
the type and time of supplementation, or whether there was 
need for calcium association.45
In another meta-analysis of randomized trials, the reduction 
in falls was observed only when vitamin D was supplemented 
at a dose of 700 IU/day or more. In this analysis, the benefits 
occurred both in institutionalized patients and outpatients. 
The results showed that when serum levels were < 24 ng/mL, 
falls were not prevented. The concomitant supplementation 
with calcium did not influence the results. The difference 
between genders was not evaluated.46
Can it be concluded that low vitamin D levels are associated 
with higher incidence and morbimortality from falls, and that its 
replacement can prevent them?
Perhaps. In the case of mortality, the evidence is indirect, 
i.e., if there are fewer falls, as observed in some studies and 
meta-analyses, and the falls are associated with increased 
mortality, then there would be a reduction in mortality with 
vitamin D supplementation. Falls occur in 30% of those older 
than 65 years, resulting in approximately 5% of fracture cases, 
and in 40% to 50% of those older than 80 years in the United 
States. This is associated with high morbidity and mortality, 
as well as high costs.47,48
Discussion
The cause-effect association between lack of vitamin D and 
bone diseases such as childhood rickets and adult osteomalacia 
is already well-established. However, recently, the interest of 
the medical and scientific community turned to its possible 
association with extra-osseous clinical manifestations, whose 
consequences to public health can be significant. 
The hypothesis that vitamin D deficiency is associated 
with the incidence or mortality caused by other diseases not 
primarily bone-related emerged in countries where prevention 
of skin cancer, with the use of sunscreen with a high protection 
factor, led to low levels of vitamin D in the population. This is 
what occurred in Australia.49
The sum of preliminary epidemiological findings and those 
from experimental studies gave rise to the concept of possible 
association between low serum vitamin D levels and several 
extra-osseous diseases. However, evidence of a cause-effect 
association between them still depends on scientific 
confirmation obtained from large studies with humans and 
the clarification of some unresolved issues. 
The first of these issues is related to the reference values of 
normality, i.e., how these parameters were defined to classify 
the body load of vitamin D as normal, insufficient, or deficient, 
and how these categories correlate with different clinical 
manifestations that are supposedly related. 
Firstly, the cutoff values for the serum levels of 25(OH)
D3  were not established in relation to the incidence or 
prevalence of health problems of population groups. They 
were calculated from the simple correlation with serum PTH 
level, which is used as reference standard. In other words, 
levels of 25(OH)D3 < 20 ng/mL (which differentiates vitamin D 
insufficiency from deficiency, according to the most often used 
criteria) trigger an increase in PTH levels above that establi shed 
as normal (intermediate outcome), but they do not necessarily 
represent a higher risk of extra-osseous disease onset50 (final 
outcome).
At this point, the identification of the real “clinical signi-
ficance” of the currently used reference values is crucial, 
especially when considering that population measurements 
of vitamin D performed in several countries have shown 
a high prevalence of low vitamin D levels, according to the 
normality, insufficiency, and deficiency criteria used to date. 
It is noteworthy that the main causes of high prevalence of low 
levels of vitamin D3 in the population are probably associated 
with habits and behaviors common to the modern lifestyle: 
sedentary life style, low exposure to sunlight, unbalanced diet, 
excessive accumulation of body fat, and abuse of topical or 
oral medications that interfere with vitamin D absorption or 
metabolism. 
Thus, the preliminary findings triggered observational and 
intervention studies that have attempted to verify whether low 
vitamin D levels were associated with increased incidence of 
or mortality from extra-osseous diseases, and whether vitamin 
D supplementation could prevent them. 
In general, a systematic review of observational studies 
(cohort or case-control studies, able to detect an association, 
but not causality) confirmed the possibility that hypovitami no-
sis D increases the incidence of or mortality from extra-osseous 
diseases, but in many cases, the results were inconsistent or 
even conflicting (Table 2).
Two questions that have not been answered adequately 
may be responsible for these findings: a) observational studies 
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are subject to misinterpretation or incomplete interpretations 
if confounder variables are not adequately controlled. 
For instance, body fat accumulation, sedentary lifestyle, 
skin color, and nutritional status, can be, simultaneously, 
causes of vitamin D deficiency and risk factors for cancer, 
cardiovascular disease, diabetes, and low immunity, therefore 
casting doubts on the proposed associations; b) there is 
the possibility of a reverse bias: chronic diseases can lead 
to patient isolation, low sun exposure, physical inactivity, 
anorexia, and worsening of diet and nutritional status, 
which lead to decreased levels of circulating 25(OH)D3. Thus, 
vitamin D measurement in these cases would serve more 
as a marker of active disease; and vitamin D deficiency, if 
diagnosed, would be the consequence, not the cause of the 
investigated disease.
 The solution to such questions depends on the performance 
of RCTs, which are intervention studies in which the incidence 
of and/or mortality from the disease (outcomes) throughout the 
study duration are compared to randomly distributed groups 
of individuals in whom basal levels of 25(OH)D3 are measured, 
and dietary supplementation of vitamin D is evaluated in 
relation to a placebo (control group). 
Table 2 shows the main results of RCTs and systematic 
reviews of the literature available to date. Contrary to the first 
impressions, there is no concrete, high methodological quality 
evidence to support the existence of a cause-effect between 
low levels of vitamin D and cancer, cardiovascular disease, and 
diabetes mellitus type 2, just as there is no conclusive evidence 
that vitamin D supplementation is able to prevent them. Some 
partial results of larger studies, however, still maintain these 
possibilities open to investigation, which deserve to be further 
studied. 
Although the data shown in this study has demonstrated 
the lack of evidence for a safe recommendation for vitamin 
D research and/or supplementation, some international 
societies have made specific recommendations. The United 
States Preventive Services Task Force (USPSTF) recommends 
vitamin D supplementation for all individuals older than 65 at 
risk for falls, regardless of the dose51 (Recommendation B). 
The recommended doses vary according to the Society. The 
Institute of Medicine recommends 600 IU for individuals aged 
51 to 70 years and 800 IU for those older than 70 years.52 The 
American Geriatrics Society recommends 800  IU for all 
individuals at risk of falling.53 The American Endocrine 
Society recommends the measurement of vitamin D3  in 
certain clinical situations including chronic use of medications 
(anticonvulsants, corticosteroids, antiretrovirals, and 
antifungal drugs), in pregnant women and infants, Blacks, 
Hispanics, obese individuals (regardless of age), and elderly 
individuals with a history of falls and non-traumatic fractures, 
osteoporosis, mal-absorption, and granulomatous diseases. It 
also recommends the measurement in patients with rickets, 
chronic kidney disease, and liver disease[8] – that is, to a 
significant portion of the population.
It is worth emphasizing that the results of the available 
studies are scarce and incomplete. Among the more obvious 
limitations, the following should be noted: a) not all diseases 
among those analyzed in the present study were assessed as 
the primary outcome in the available studies and reviews; b) the 
study populations were heterogeneous, and the results cannot 
always be extrapolated to the general population; c) the basal 
levels of 25(OH)D3 were not always measured, and the dose and 
type of vitamin D supplementation varied significantly among 
the studies; d) the presence of comorbidities and consumption 
of chemical substances among the participants were not 
always adequately controlled; and e) time of follow-up in most 
studies may have been insufficient. As there are hundreds of 
ongoing registered RCTs on the subject around the world, 
within a few years valuable information should be available 
to guide clinical practice. 
For the time being, healthy lifestyle habits, such as regular 
physical activity, moderate sun exposure, balanced diet, weight 
control, and controlled consumption of chemical substances 
still appear to be the most effective way to promote health and 
prevent disease, whether or not related to hypovitaminosis D.
Conclusion
Based on the best scientific evidence available to date, it is 
not possible to establish a causal association between low 
serum levels of 25(OH)D3 and cancer, cardiovascular disease, 
and diabetes mellitus type 2. Therefore, vitamin D routine 
measurement or dietary supplementation is not recommended 
for preventive purposes in the general population. It is 
possible that periodic measurement of 25(OH)D3 and vitamin 
supplementation, when necessary, can bring benefits to 
women older than 60 to 65 years, non-institutionalized, with 
a history or high risk of repeated falls.
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